# Dravet syndrome FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/dravet-syndrome

> 4 upcoming FDA catalysts in Dravet syndrome: zorevunersen (STOK) on March 2027 (primary completion); zorevunersen (STOK) on Mar to Jun 2027 (topline data readout); zorevunersen (stk-001, STOK) on Mar to Jun 2029 (topline data readout); zorevunersen (stk-001, STOK) on March 2029 (primary completion).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| August 11, 2025 | [Zorevunersen trial start](https://sec-api.dev/pdufa/zorevunersen) | STOK | Dravet syndrome | completed | "On August 11, 2025, Stoke Therapeutics, Inc. (the "Company") and Biogen International GmbH issued a joint press release (the "Press Release") announcing that the first patient has been dosed in the global Phase 3 EMPEROR study of zorevunersen for the treatment of Dravet syndrome." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1623526/000119312525177433/d64221d8k.htm)) |
| March 2027 | [Zorevunersen primary completion](https://sec-api.dev/pdufa/zorevunersen) | STOK | Dravet Syndrome | scheduled | "NCT06872125 (A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-03 (ESTIMATED); Lead Sponsor Stoke Therapeutics, Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06872125)) |
| Mar to Jun 2027 | [Zorevunersen topline data readout](https://sec-api.dev/pdufa/zorevunersen) | STOK | Dravet Syndrome | scheduled | "NCT06872125 (A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-03 (ESTIMATED); Lead Sponsor Stoke Therapeutics, Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06872125)) |
| Mar to Jun 2029 | [Zorevunersen (stk-001) topline data readout](https://sec-api.dev/pdufa/zorevunersen-stk-001) | STOK | Dravet Syndrome | scheduled | "NCT04740476 (An Open-Label Extension Study of STK-001 for Patients With Dravet Syndrome): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2029-03-31 (ESTIMATED); Lead Sponsor Stoke Therapeutics, Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04740476)) |
| March 2029 | [Zorevunersen (stk-001) primary completion](https://sec-api.dev/pdufa/zorevunersen-stk-001) | STOK | Dravet Syndrome | scheduled | "NCT04740476 (An Open-Label Extension Study of STK-001 for Patients With Dravet Syndrome): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2029-03-31 (ESTIMATED); Lead Sponsor Stoke Therapeutics, Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04740476)) |

## Drugs

- [Zorevunersen](https://sec-api.dev/pdufa/zorevunersen) (STOK)
- [Zorevunersen (stk-001)](https://sec-api.dev/pdufa/zorevunersen-stk-001) (STOK)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/dravet-syndrome.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Dravet syndrome FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/dravet-syndrome

```bibtex
@misc{secapidev_indications_dravet_syndrome_20261116,
  title        = {Dravet syndrome FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/dravet-syndrome}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_dravet_syndrome_20261116","title":"Dravet syndrome FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/dravet-syndrome","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
